Results 241 to 250 of about 157,671 (305)
Some of the next articles are maybe not open access.
New Scientist, 2021
Widely used in the UK, the Oxford/AstraZeneca vaccine is effective at preventing deaths and ...
openaire +1 more source
Widely used in the UK, the Oxford/AstraZeneca vaccine is effective at preventing deaths and ...
openaire +1 more source
Financial Analysis of AstraZeneca
SSRN Electronic Journal, 2021The business under our conversation is AstraZeneca Oxford is a British global pharma industry, it was established in April 1999, the settlement is in Cambridge, UK. It is the Pharma fabricating industry that produces distinctive live-saving medications to the world. They work on medication for the treatment of oncology and Biopharmaceuticals.
Khuloud Al Ghanem +6 more
openaire +1 more source
IDrugs : the investigational drugs journal, 2003
NO-naproxen, consisting of the NSAID naproxen linked to a nitric oxide (NO) moiety, is under development by AstraZeneca plc, under license from NicOx SA, for the potential treatment of acute/chronic pain.
openaire +2 more sources
NO-naproxen, consisting of the NSAID naproxen linked to a nitric oxide (NO) moiety, is under development by AstraZeneca plc, under license from NicOx SA, for the potential treatment of acute/chronic pain.
openaire +2 more sources
Chemical & Engineering News Archive, 2013
The bicycle-filled city of Cambridge, England, has been closely tied to biotechnology since 1953, when Francis H. C. Crick and James D. Watson discovered the structure of DNA in the University of Cambridge’s Cavendish building. Other luminaries that once studied at the university include Isaac Newton and Charles Darwin.
openaire +1 more source
The bicycle-filled city of Cambridge, England, has been closely tied to biotechnology since 1953, when Francis H. C. Crick and James D. Watson discovered the structure of DNA in the University of Cambridge’s Cavendish building. Other luminaries that once studied at the university include Isaac Newton and Charles Darwin.
openaire +1 more source
European J. of International Management, 2019
The Pfizer-AstraZeneca case shows how an acquisition target can successfully repel an attempted takeover by engaging with positively disposed stakeholders and managing communications and the news agenda. The company communicated clearly, consistently and powerfully throughout the process and could benefit from a natural, if temporary, coalition of ...
Asja Hot +3 more
openaire +1 more source
The Pfizer-AstraZeneca case shows how an acquisition target can successfully repel an attempted takeover by engaging with positively disposed stakeholders and managing communications and the news agenda. The company communicated clearly, consistently and powerfully throughout the process and could benefit from a natural, if temporary, coalition of ...
Asja Hot +3 more
openaire +1 more source
AstraZeneca to acquire Alexion
C&EN Global Enterprise, 2020In a bid to expand into rare diseases, AstraZeneca is set to buy Alexion Pharmaceuticals for $39 billion.
openaire +1 more source
The Evolution of SEND at AstraZeneca
Regulatory Toxicology and Pharmacology, 2021Claire Kent +4 more
openaire +2 more sources
Current opinion in investigational drugs (London, England : 2000), 2002
AstraZeneca (formerly Astra) is developing ximelagatran, an orally active thrombin inhibitor and prodrug of melagatran, for the potential prevention and treatment of venous thromboembolism (VTE) in hip and knee replacement, for prevention of stroke in atrialfibrillation (AF) and for post acute coronary syndrome.
openaire +1 more source
AstraZeneca (formerly Astra) is developing ximelagatran, an orally active thrombin inhibitor and prodrug of melagatran, for the potential prevention and treatment of venous thromboembolism (VTE) in hip and knee replacement, for prevention of stroke in atrialfibrillation (AF) and for post acute coronary syndrome.
openaire +1 more source